Banerjee Remedies Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.80 M
- Company Age 23 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -81.70%
- Profit Growth -406.21%
- Ebitda 29.31%
- Net Worth -219.96%
- Total Assets -1.19%
About Banerjee Remedies
Banerjee Remedies Private Limited (BRPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 23 October 2001 and has a history of 23 years and three months. Its registered office is in Hooghly, West Bengal, India.
The Corporate was formerly known as Artra Impex Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.80 M, as per Ministry of Corporate Affairs (MCA) records.
Arnab Banerjee and Munmun Banerjee serve as directors at the Company.
Company Details
-
Location
Hooghly, West Bengal, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74900WB2001PTC093880
-
Company No.
093880
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Oct 2001
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Banerjee Remedies?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arnab Banerjee
|
Director | 06-Jun-2017 | Current |
|
Munmun Banerjee
|
Director | 06-Jun-2017 | Current |
Financial Performance of Banerjee Remedies.
Banerjee Remedies Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 81.7% decrease. The company also saw a substantial fall in profitability, with a 406.21% decrease in profit. The company's net worth observed a substantial decline by a decrease of 219.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Banerjee Remedies?
In 2020, Banerjee Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Banerjee Distributors Private LimitedArnab Banerjee and Munmun Banerjee are mutual person
-
Banerjee Eduservices LlpArnab Banerjee and Munmun Banerjee are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Banerjee Remedies?
Unlock and access historical data on people associated with Banerjee Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Banerjee Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Banerjee Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
